4 hours ago
https://www.noemamag.com/what-chinas-gen...-industry/
INTRO: In March 2023, four-year-old Mei in Shanghai was diagnosed with a rare genetic mutation linked to developmental delay and autism-like traits. Although her condition was mild and she improved with therapy and special education, her parents remained worried about her future. Hopeful for a cure, they paid Qiu Zilong, a renowned neuroscientist at Shanghai Jiao Tong University, and his team $860,000 to develop a customized gene therapy. The treatment, which used adeno-associated viruses to deliver gene editors to the brain, had been approved by Xinhua Hospital, a leading hospital for rare diseases.
On March 24, 2025, trillions of viral particles carrying gene editors were injected into Mei’s spinal cord. She soon developed a fever and kidney failure and died within days. A year later, Qiu’s team published its preclinical findings in Nature. Mei’s case was hailed by Chinese media as “a world-class breakthrough.” Mei’s death and her family’s financial support were not mentioned.
Deaths in clinical trials are not unusual. What is shocking are the regulatory lapses revealed by an investigation published this July in Science and subsequently corroborated by a separate investigation conducted by the Shanghai municipal government, which released its findings last week. The treatment’s consent form, for instance, didn’t warn of the possibility of death. The hospital had approved treatment before toxicology findings showing liver and kidney damage in monkeys that received similar treatments. And, among other crucial omissions, the researchers failed to disclose Mei’s death.
Apparently, this was not an isolated incident. Several researchers told me that Chinese hospitals commonly fail to disclose adverse events. On Aug. 5, STAT reported another death in a gene-editing trial led by Shanghai-based HuidaGene, an incident that had remained undisclosed for about 15 months. (The Chinese team published their findings, including the fatal case, in Cell on Oct. 26.) A founder of a rare-disease organization in China told me, on condition of anonymity for fear of political repercussions, that she had encountered other trials for genetic disorders in which deaths had gone unreported. Recent revelations of undisclosed deaths in clinical trials conducted in China have prompted warnings against the use of Chinese data in U.S. drug development.
As someone who has reported on China’s ethical governance for two decades, this all feels like déjà vu. Since modern bioethics was introduced to China in the late 1980s, its history has been punctuated by one scandal after another — often fueled by hype surrounding emerging technologies — that have earned the country a reputation as biotechnology’s “Wild East.” (MORE - details)
INTRO: In March 2023, four-year-old Mei in Shanghai was diagnosed with a rare genetic mutation linked to developmental delay and autism-like traits. Although her condition was mild and she improved with therapy and special education, her parents remained worried about her future. Hopeful for a cure, they paid Qiu Zilong, a renowned neuroscientist at Shanghai Jiao Tong University, and his team $860,000 to develop a customized gene therapy. The treatment, which used adeno-associated viruses to deliver gene editors to the brain, had been approved by Xinhua Hospital, a leading hospital for rare diseases.
On March 24, 2025, trillions of viral particles carrying gene editors were injected into Mei’s spinal cord. She soon developed a fever and kidney failure and died within days. A year later, Qiu’s team published its preclinical findings in Nature. Mei’s case was hailed by Chinese media as “a world-class breakthrough.” Mei’s death and her family’s financial support were not mentioned.
Deaths in clinical trials are not unusual. What is shocking are the regulatory lapses revealed by an investigation published this July in Science and subsequently corroborated by a separate investigation conducted by the Shanghai municipal government, which released its findings last week. The treatment’s consent form, for instance, didn’t warn of the possibility of death. The hospital had approved treatment before toxicology findings showing liver and kidney damage in monkeys that received similar treatments. And, among other crucial omissions, the researchers failed to disclose Mei’s death.
Apparently, this was not an isolated incident. Several researchers told me that Chinese hospitals commonly fail to disclose adverse events. On Aug. 5, STAT reported another death in a gene-editing trial led by Shanghai-based HuidaGene, an incident that had remained undisclosed for about 15 months. (The Chinese team published their findings, including the fatal case, in Cell on Oct. 26.) A founder of a rare-disease organization in China told me, on condition of anonymity for fear of political repercussions, that she had encountered other trials for genetic disorders in which deaths had gone unreported. Recent revelations of undisclosed deaths in clinical trials conducted in China have prompted warnings against the use of Chinese data in U.S. drug development.
As someone who has reported on China’s ethical governance for two decades, this all feels like déjà vu. Since modern bioethics was introduced to China in the late 1980s, its history has been punctuated by one scandal after another — often fueled by hype surrounding emerging technologies — that have earned the country a reputation as biotechnology’s “Wild East.” (MORE - details)